Williams-Sonoma Free cash flow increased by 108.0% to $515.99M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 8.9%, from $566.27M to $515.99M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows relatively stable performance with a -2.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $196.52M | $200.87M | $249.94M | $497.30M | $113.33M | $121.71M | $119.10M | $344.56M | $292.50M | $329.61M | $248.48M | $621.23M | $187.28M | $215.06M | $170.05M | $566.27M | $60.70M | $230.69M | $248.08M | $515.99M |
| QoQ Change | — | +2.2% | +24.4% | +99.0% | -77.2% | +7.4% | -2.1% | +189.3% | -15.1% | +12.7% | -24.6% | +150.0% | -69.9% | +14.8% | -20.9% | +233.0% | -89.3% | +280.0% | +7.5% | +108.0% |
| YoY Change | — | — | — | — | -42.3% | -39.4% | -52.3% | -30.7% | +158.1% | +170.8% | +108.6% | +80.3% | -36.0% | -34.8% | -31.6% | -8.8% | -67.6% | +7.3% | +45.9% | -8.9% |